Literature DB >> 15549354

MRI: role in optimising treatment.

Anthony Traboulsee1.   

Abstract

Magnetic resonance imaging (MRI) is an extremely sensitive diagnostic tool that provides us with highly detailed images of the living human brain. Since it was first applied to multiple sclerosis (MS) in clinical trials in the 1980s, MRI has become established as a reliable, sensitive and reproducible technique for studying the pathophysiology of this complex disease. It has provided a variety of surrogate measures for clinical trials, and continues to offer new methods for the detection and monitoring of the physical and chemical changes in the brains of living patients. The unique sensitivity of conventional MRI measures for detecting MS pathology has made MRI an attractive tool for optimising treatment in clinical practice for individual patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549354     DOI: 10.1007/s00415-004-1506-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.

Authors:  D K Li; G J Zhao; D W Paty
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

2.  Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden.

Authors:  S J Khoury; C R Guttmann; E J Orav; M J Hohol; S S Ahn; L Hsu; R Kikinis; G A Mackin; F A Jolesz; H L Weiner
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

3.  Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy.

Authors:  G M Nesbit; G S Forbes; B W Scheithauer; H Okazaki; M Rodriguez
Journal:  Radiology       Date:  1991-08       Impact factor: 11.105

4.  Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.

Authors:  H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

5.  Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.

Authors:  A Traboulsee; J Dehmeshki; Kevin R Peters; C M Griffin; P A Brex; N Silver; O Ciccarrelli; D T Chard; G J Barker; A J Thompson; D H Miller
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

Review 6.  Neuropathology of multiple sclerosis-new concepts.

Authors:  Barbara Kornek; Hans Lassmann
Journal:  Brain Res Bull       Date:  2003-08-15       Impact factor: 4.077

7.  Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS.

Authors:  A Traboulsee; J Dehmeshki; P A Brex; C M Dalton; D Chard; G J Barker; G T Plant; D H Miller
Journal:  Neurology       Date:  2002-07-09       Impact factor: 9.910

8.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS.

Authors:  P A Brex; R Jenkins; N C Fox; W R Crum; J I O'Riordan; G T Plant; D H Miller
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.

Authors:  D T Chard; C M Griffin; M A McLean; P Kapeller; R Kapoor; A J Thompson; D H Miller
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.